Safety, efficacy and pharmacokinetics of a new 10% liquid intravenous immunoglobulin (IVIG) in patients with primary immunodeficiency.
about
Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases.Pneumococcal Antibody Titers: A Comparison of Patients Receiving Intravenous Immunoglobulin Versus Subcutaneous Immunoglobulin.Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients.A new intravenous immunoglobulin (BIVIGAM®) for primary humoral immunodeficiency.Evidence that NF-κB and MAPK Signaling Promotes NLRP Inflammasome Activation in Neurons Following Ischemic Stroke.Efficacy and Safety of Human Intravenous Immunoglobulin 10% (Panzyga®) in Patients with Primary Immunodeficiency Diseases: a Two-Stage, Multicenter, Prospective, Open-Label Study.Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerability.Flebogamma(®) 5 % DIF Intravenous Immunoglobulin for Replacement Therapy in Children with Primary Immunodeficiency Diseases.Development, manufacturing and characterization of a highly purified, liquid immunoglobulin g preparation from human plasma.Surveillance study on the tolerability and safety of Flebogamma® DIF (10% and 5% intravenous immunoglobulin) in adult and pediatric patients.New insights in the use of immunoglobulins for the management of immune deficiency (PID) patients.Emerging Paradigm of Primary Immunodeficiency Disease: Individualizing Immunoglobulin Dose and Delivery to Enhance Outcomes.An open, prospective trial investigating the pharmacokinetics and safety, and the tolerability of escalating infusion rates of a 10% human normal immunoglobulin for intravenous infusion (IVIg), BT090, in patients with primary immunodeficiency diseasApplication of Antibody-Mediated Therapy for Treatment and Prevention of Clostridium difficile Infection.Timing of infections in patients with primary immunodeficiencies treated with intravenous immunoglobulin (IVIg)
P2860
Q36196688-3A7F6502-0EF8-48AF-B45C-570DF80C68F1Q37695737-4DBD6917-F5B9-4016-A3C6-E3A291E3FEE5Q38042583-02317AB9-1A1C-4157-884B-B42FE7B0F320Q38188031-E30802C1-41F4-4BB3-AEF5-9085477B4CA3Q38769999-66004946-2458-4D0B-B862-C849FF0D6624Q40045651-C55CE2B6-26B0-499B-B2C3-F2B31629AAF2Q40596658-A183C236-9E15-4ACA-9691-70F81A838393Q40639960-20B17F24-C6EC-4282-BD84-DF28D69FFDB0Q42119487-1C472EE9-6FEB-4D2D-80A4-805D538630F5Q42183204-9AFA002B-D165-4B17-8D95-8598AF1CC7E1Q45012826-53F69131-6778-4B28-8ED3-1421E29CB1F2Q46004431-42AB9E0A-83F1-4C0B-AD64-2F239162C167Q50556522-27523EE8-29B7-4FA9-81BF-AA4E2C96FDB7Q55516782-0A2D9BA7-49ED-4664-B1F2-9E3F16B6EB77Q58787289-9670A611-D0E9-45F2-A910-5A2674874ABB
P2860
Safety, efficacy and pharmacokinetics of a new 10% liquid intravenous immunoglobulin (IVIG) in patients with primary immunodeficiency.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Safety, efficacy and pharmacok ...... with primary immunodeficiency.
@ast
Safety, efficacy and pharmacok ...... with primary immunodeficiency.
@en
type
label
Safety, efficacy and pharmacok ...... with primary immunodeficiency.
@ast
Safety, efficacy and pharmacok ...... with primary immunodeficiency.
@en
prefLabel
Safety, efficacy and pharmacok ...... with primary immunodeficiency.
@ast
Safety, efficacy and pharmacok ...... with primary immunodeficiency.
@en
P2093
P2860
P1476
Safety, efficacy and pharmacok ...... with primary immunodeficiency.
@en
P2093
Daniel Suez
David Elkayam
Harry Schroeder
Isaac Melamed
James Harris
Joseph A Church
Mark Ballow
Mark Stein
Martha White
P2860
P2888
P304
P356
10.1007/S10875-012-9656-5
P577
2012-03-06T00:00:00Z